Next Article in Journal / Special Issue
Prevalence of Antibodies against Hantaviruses in Serum and Saliva of Adults Living or Working on Farms in Yorkshire, United Kingdom
Previous Article in Journal / Special Issue
Analysis of an Outbreak of Hemorrhagic Fever with Renal Syndrome in College Students in Xi’an, China
Viruses 2014, 6(2), 516-523; doi:10.3390/v6020516
Article

Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters

1
,
1,2
,
3
 and
1,*
Received: 11 December 2013 / Revised: 20 January 2014 / Accepted: 22 January 2014 / Published: 31 January 2014
(This article belongs to the Special Issue Hantaviruses)
View Full-Text   |   Download PDF [413 KB, uploaded 12 May 2015]   |   Browse Figures

Abstract

Andes virus (ANDV) is highly pathogenic in humans and is the primary etiologic agent of hantavirus cardiopulmonary syndrome (HCPS) in South America. Case-fatality rates are as high as 50% and there are no approved vaccines or specific therapies for infection. Our laboratory has recently developed a replication-competent recombinant vesicular stomatitis virus (VSV)-based vaccine that expressed the glycoproteins of Andes virus in place of the native VSV glycoprotein (G). This vaccine is highly efficacious in the Syrian hamster model of HCPS when given 28 days before challenge with ANDV, or when given around the time of challenge (peri-exposure), and even protects when administered post-exposure. Herein, we sought to test the durability of the immune response to a single dose of this vaccine in Syrian hamsters. This vaccine was efficacious in hamsters challenged intranasally with ANDV 6 months after vaccination (p = 0.025), but animals were not significantly protected following 1 year of vaccination (p = 0.090). The decrease in protection correlated with a reduction of measurable neutralizing antibody responses, and suggests that a more robust vaccination schedule might be required to provide long-term immunity.
Keywords: Andes virus; vaccine; durability; antibody response; hantavirus Andes virus; vaccine; durability; antibody response; hantavirus
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Prescott, J.; DeBuysscher, B.L.; Brown, K.S.; Feldmann, H. Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters. Viruses 2014, 6, 516-523.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert